A Phase 4 interventional study of Eltrombopag olamine in Purpura, Thrombocytopaenic, Idiopathic, sponsored by GlaxoSmithKline. Completed at 34 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-12.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A open-label, multi-center 2-year safety study to ascertain the baseline levels of bone marrow fibers in previously treated adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) and to evaluate the long-term effect of eltrombopag on bone marrow fibers. The study will also describe the long-term safety and tolerability of oral eltrombopag treatment in subjects with chronic ITP.
This is a phase IV, open-label safety study, designed to determine baseline levels of bone marrow fibers in previously treated adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP)and to evaluate the long-term effect of eltrombopag on bone marrow reticulin and/or collagen fibers.
The duration of the screening period is up to 8 weeks. Eltrombopag will be administered for at least 2-years followed by a 4-week follow-up period. Bone marrow biopsies will be performed at screening, after 1-year and 2-years of eltrombopag treatment, and at early withdrawal of treatment. The screening bone marrow biopsy should be performed within 8 weeks of planned start of study medication and the bone marrow biopsy block must be available for central laboratory processing.
32 studies on the registry are indexed under Purpura, Thrombocytopenic; 6 are open to participants now.
This study's enrollment of 167 is above the median of 54 across 22 interventional studies indexed under Purpura, Thrombocytopenic.
Browse Purpura, Thrombocytopenic studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within Purpura, Thrombocytopenic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Purpura. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Exception: Subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral eltrombopag once daily, starting dose 50 mg (or 25 mg for subjects of East Asian ancestry).
Drug: Eltrombopag olamine
Thrombopoietin receptor agonist
Number of Participants With Bone Marrow (BM) Fibers of MF Grade 0, 1, 2 and 3 on the European Consensus (EC) Scale at Baseline
The evaluation of fibrosis was performed using BM biopsies in which the amount of fibrosis was assessed by the EC Grading Scale. This method distinguishes four degrees of fibrosis (myelofibrosis \[MF\]-0 to MF-3). MF Grade (G) 0 is scattered linear reticulin with no intersections (cross-overs) corresponding to normal BM; MF Grade 1 is loose network of reticulin with many intersections, especially in perivascular areas; MF Grade 2 is diffuse and dense increase in reticulin with extensive intersections, occasionally with only focal bundles of collagen and/or focal osteosclerosis; MF Grade 3 is diffuse and dense increase in reticulin with extensive intersections with coarse bundles of collagen, often associated with significant osteosclerosis. Baseline is defined as the most recent centrally-reviewed BM biopsy prior to first dose of eltrombopag in the study.
Time frame: Baseline
Number of Participants With a Positive or Negative Collagen Level at Baseline
The number of participants with a positive or negative collagen level was analyzed. Baseline is defined as the most recent centrally-reviewed BM biopsy prior to first dose of eltrombopag in the study.
Time frame: Baseline
Number of Participants With Indicated Grade Change From Baseline in the EC Grading Scale at 1 Year
The change from baseline to on-treatment assessments of European Consensus (EC) scale was analyzed. On-treatment is defined as during the treatment period (including dose interruptions) and up to 14 days after the end of the treatment period. MF-0 is scattered linear reticulin with no intersections (cross-overs) corresponding to normal BM; MF-1 is loose network of reticulin with many intersections, especially in perivascular areas; MF-2 is diffuse and dense increase in reticulin with extensive intersections, occasionally with only focal bundles of collagen and/or focal osteosclerosis; MF-3 is diffuse and dense increase in reticulin with extensive intersections with coarse bundles of collagen, often associated with significant osteosclerosis. Baseline is defined as the most recent centrally-reviewed BM biopsy prior to first dose of eltrombopag in the study.
Time frame: Baseline and 1 year
Number of Participants With Indicated Change From Baseline in the EC Grading Scale at 2 Years
The change from baseline to on-treatment assessments of European Consensus (EC) scale was analyzed. On-treatment is defined as during the treatment period (including dose interruptions) and up to 14 days after the end of the treatment period. MF-0 is scattered linear reticulin with no intersections (cross-overs) corresponding to normal BM; MF-1 is loose network of reticulin with many intersections, especially in perivascular areas; MF-2 is diffuse and dense increase in reticulin with extensive intersections, occasionally with only focal bundles of collagen and/or focal osteosclerosis; MF-3 is diffuse and dense increase in reticulin with extensive intersections with coarse bundles of collagen, often associated with significant osteosclerosis. Baseline is defined as the most recent centrally-reviewed BM biopsy prior to first dose of eltrombopag in the study.
Time frame: Baseline and 2 years
Number of Participants With a Positive or Negative Collagen Level at 1 Year
The change from Baseline to on-treatment assessments of collagen level was analyzed. On-treatment is defined as during the treatment period (including dose interruptions) and up to 14 days after the end of the treatment period.
Time frame: 1 year
Number of Participants With a Positive or Negative Collagen Level at 2 Year
The change from Baseline to on-treatment assessments of collagen level was analyzed. On-treatment is defined as during the treatment period (including dose interruptions) and up to 14 days after the end of the treatment period.
Time frame: 2 years
Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters at Any Time Post-Baseline During the Study
Clinical chemistry parameters were summarized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0: G0, none; G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Clinical chemistry parameters included: albumin, alkaline phosphatase (ALP), alanine amino transferase (ALT), aspartate amino transferase (AST), total bilirubin, calcium (hypercalcemia), calcium (hypocalcemia), potassium (hyperkalemia), potassium (hypokalemia), sodium (hypernatremia), sodium (hyponatremia), inorganic phosphorus and creatinine. Baseline values were obtained at Day 1. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). The maximum post-Baseline toxicity grade includes any scheduled or unscheduled post-Baseline assessment during.
Time frame: From Week 1 up to Week 104 and up to 6 months follow-up (4 weeks for most participants) (up to approximately 2.5 years)
Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Hematology Parameters at Any Time Post-Baseline During the Study
Hematology parameters were summarized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0: G0, none; G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Hematology parameters included: hemoglobin (increased), hemoglobin (anemia), lymphocyte count (increased), lymphocyte count (decreased), total absolute neutrophil count (ANC), platelet count and white blood cell (WBC) count. Baseline values were obtained at Day 1. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). The maximum post-Baseline toxicity grade includes any scheduled or unscheduled post-Baseline assessment during.
Time frame: From Week 1 up to Week 104 and up to 6 months follow-up (4 weeks for most participants) (up to approximately 2.5 years)
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) Started On-therapy + 1 Day, >1 to 30 Days Post Therapy and >30 Days Post Therapy
On-therapy + 1 day is defined as AEs started between the first dose of eltrombopag and up to the day after the last dose of eltrombopag; \>1 to 30 days post therapy is defined as AEs that started more than 1 day and up to 30 days after the last dose of eltrombopag; \>30 days post therapy is defined as AEs started that started more than 30 days after the last dose of eltrombopag. An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.
Time frame: From Week 1 up to Week 104 and up to 6 months follow-up (4 weeks for most participants) (up to approximately 2.5 years)
| Milestone | Eltrombopag |
|---|---|
| Started | 162 |
| Completed | 118 |
| Not completed | 44 |
| Withdrew: Adverse event | 22 |
| Withdrew: Lack of efficacy | 11 |
| Withdrew: Withdrawal by subject | 7 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Physician decision | 1 |
The evaluation of fibrosis was performed using BM biopsies in which the amount of fibrosis was assessed by the EC Grading Scale. This method distinguishes four degrees of fibrosis (myelofibrosis \[MF\]-0 to MF-3). MF Grade (G) 0 is scattered linear reticulin with no intersections (cross-overs) corresponding to normal BM; MF Grade 1 is loose network of reticulin with many intersections, especially in perivascular areas; MF Grade 2 is diffuse and dense increase in reticulin with extensive intersections, occasionally with only focal bundles of collagen and/or focal osteosclerosis; MF Grade 3 is diffuse and dense increase in reticulin with extensive intersections with coarse bundles of collagen, often associated with significant osteosclerosis. Baseline is defined as the most recent centrally-reviewed BM biopsy prior to first dose of eltrombopag in the study.
| Participants | Eltrombopag |
|---|---|
| MF-0 | 150 |
| MF-1 | 9 |
| MF-2 | 0 |
| MF-3 | 0 |
The number of participants with a positive or negative collagen level was analyzed. Baseline is defined as the most recent centrally-reviewed BM biopsy prior to first dose of eltrombopag in the study.
| Participants | Eltrombopag |
|---|---|
| Negative | 159 |
| Positive | 0 |
The change from baseline to on-treatment assessments of European Consensus (EC) scale was analyzed. On-treatment is defined as during the treatment period (including dose interruptions) and up to 14 days after the end of the treatment period. MF-0 is scattered linear reticulin with no intersections (cross-overs) corresponding to normal BM; MF-1 is loose network of reticulin with many intersections, especially in perivascular areas; MF-2 is diffuse and dense increase in reticulin with extensive intersections, occasionally with only focal bundles of collagen and/or focal osteosclerosis; MF-3 is diffuse and dense increase in reticulin with extensive intersections with coarse bundles of collagen, often associated with significant osteosclerosis. Baseline is defined as the most recent centrally-reviewed BM biopsy prior to first dose of eltrombopag in the study.
| Participants | Eltrombopag |
|---|---|
| MF-0 to MF-0 | 82 |
| MF-0 to MF-1 | 33 |
| MF-0 to MF-2 | 2 |
| MF-0 to MF-3 | 2 |
| MF-1 to MF-0 | 3 |
| MF-1 to MF-1 | 2 |
| MF-1 to MF-2 | 1 |
| MF-1 to MF-3 | 0 |
| MF-2 to MF-0 | 0 |
| MF-2 to MF-1 | 0 |
| MF-2 to MF-2 | 0 |
| MF-2 to MF-3 | 0 |
| MF-3 to MF-0 | 0 |
| MF-3 to MF-1 | 0 |
| MF-3 to MF-2 | 0 |
| MF-3 to MF-3 | 0 |
| Missing to MF-0 | 2 |
| Missing to MF-1 | 0 |
| Missing to MF-2 | 0 |
| Missing to MF-3 | 0 |
The change from baseline to on-treatment assessments of European Consensus (EC) scale was analyzed. On-treatment is defined as during the treatment period (including dose interruptions) and up to 14 days after the end of the treatment period. MF-0 is scattered linear reticulin with no intersections (cross-overs) corresponding to normal BM; MF-1 is loose network of reticulin with many intersections, especially in perivascular areas; MF-2 is diffuse and dense increase in reticulin with extensive intersections, occasionally with only focal bundles of collagen and/or focal osteosclerosis; MF-3 is diffuse and dense increase in reticulin with extensive intersections with coarse bundles of collagen, often associated with significant osteosclerosis. Baseline is defined as the most recent centrally-reviewed BM biopsy prior to first dose of eltrombopag in the study.
| Participants | Eltrombopag |
|---|---|
| MF-0 to MF-0 | 79 |
| MF-0 to MF-1 | 9 |
| MF-0 to MF-2 | 0 |
| MF-0 to MF-3 | 0 |
| MF-1 to MF-0 | 2 |
| MF-1 to MF-1 | 1 |
| MF-1 to MF-2 | 0 |
| MF-1 to MF-3 | 0 |
| MF-2 to MF-0 | 0 |
| MF-2 to MF-1 | 0 |
| MF-2 to MF-2 | 0 |
| MF-2 to MF-3 | 0 |
| MF-3 to MF-0 | 0 |
| MF-3 to MF-1 | 0 |
| MF-3 to MF-2 | 0 |
| MF-3 to MF-3 | 0 |
| Missing to MF-0 | 2 |
| Missing to MF-1 | 0 |
| Missing to MF-2 | 0 |
| Missing to MF-3 | 0 |
The change from Baseline to on-treatment assessments of collagen level was analyzed. On-treatment is defined as during the treatment period (including dose interruptions) and up to 14 days after the end of the treatment period.
| Participants | Eltrombopag |
|---|---|
| Negative to Negative | 120 |
| Negative to Positive | 5 |
| Positive to Negative | 0 |
| Positive to Positive | 0 |
| Missing to Negative | 2 |
| Missing to Positive | 0 |
The change from Baseline to on-treatment assessments of collagen level was analyzed. On-treatment is defined as during the treatment period (including dose interruptions) and up to 14 days after the end of the treatment period.
| Participants | Eltrombopag |
|---|---|
| Negative to Negative | 90 |
| Negative to Positive | 1 |
| Positive to Negative | 0 |
| Positive to Positive | 0 |
| Missing to Negative | 2 |
| Missing to Positive | 0 |
Clinical chemistry parameters were summarized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0: G0, none; G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Clinical chemistry parameters included: albumin, alkaline phosphatase (ALP), alanine amino transferase (ALT), aspartate amino transferase (AST), total bilirubin, calcium (hypercalcemia), calcium (hypocalcemia), potassium (hyperkalemia), potassium (hypokalemia), sodium (hypernatremia), sodium (hyponatremia), inorganic phosphorus and creatinine. Baseline values were obtained at Day 1. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). The maximum post-Baseline toxicity grade includes any scheduled or unscheduled post-Baseline assessment during.
| Participants | Eltrombopag |
|---|---|
| Albumin, G0, n=162 | 151 |
| Albumin, G1, n=162 | 5 |
| Albumin, G2, n=162 | 6 |
| Albumin, G3, n=162 | 0 |
| Albumin, G4, n=162 | 0 |
| ALP, G0, n=162 | 125 |
| ALP, G1, n=162 | 35 |
| ALP, G2, n=162 | 2 |
| ALP, G3, n=162 | 0 |
| ALP, G4, n=162 | 0 |
| ALT, G0, n=162 | 109 |
| ALT, G1, n=162 | 37 |
| ALT, G2, n=162 | 8 |
| ALT, G3, n=162 | 7 |
| ALT, G4, n=162 | 1 |
| AST, G0, n=162 | 99 |
| AST, G1, n=162 | 48 |
| AST, G2, n=162 | 8 |
| AST, G3, n=162 | 5 |
| AST, G4, n=162 | 2 |
| Total bilirubin, G0, n=162 | 103 |
| Total bilirubin, G1, n=162 | 40 |
| Total bilirubin, G2, n=162 | 17 |
| Total bilirubin, G3, n=162 | 2 |
| Total bilirubin, G4, n=162 | 0 |
| Calcium (hypercalcemia), G0, n=162 | 159 |
| Calcium (hypercalcemia), G1, n=162 | 2 |
| Calcium (hypercalcemia), G2, n=162 | 1 |
| Calcium (hypercalcemia), G3, n=162 | 0 |
| Calcium (hypercalcemia), G4, n=162 | 0 |
| Calcium (hypocalcemia), G0, n=162 | 92 |
| Calcium (hypocalcemia), G1, n=162 | 57 |
| Calcium (hypocalcemia), G2, n=162 | 12 |
| Calcium (hypocalcemia), G3, n=162 | 0 |
| Calcium (hypocalcemia), G4, n=162 | 1 |
| Potassium (hyperkalemia), G0, n=162 | 138 |
| Potassium (hyperkalemia), G1, n=162 | 14 |
| Potassium (hyperkalemia), G2, n=162 | 5 |
| Potassium (hyperkalemia), G3, n=162 | 5 |
| Potassium (hyperkalemia), G4, n=162 | 0 |
| Potassium (hypokalemia), G0, n=162 | 123 |
| Potassium (hypokalemia), G1, n=162 | 35 |
| Potassium (hypokalemia), G2, n=162 | 0 |
| Potassium (hypokalemia), G3, n=162 | 4 |
| Potassium (hypokalemia), G4, n=162 | 0 |
| Sodium (hypernatremia), G0, n=162 | 138 |
| Sodium (hypernatremia), G1, n=162 | 20 |
| Sodium (hypernatremia), G2, n=162 | 2 |
| Sodium (hypernatremia), G3, n=162 | 2 |
| Sodium (hypernatremia), G4, n=162 | 0 |
| Sodium (hyponatremia), G0, n=162 | 137 |
| Sodium (hyponatremia), G1, n=162 | 21 |
| Sodium (hyponatremia), G2, n=162 | 0 |
| Sodium (hyponatremia), G3, n=162 | 3 |
| Sodium (hyponatremia), G4, n=162 | 1 |
| Inorganic phosphorus, G0, n=162 | 100 |
| Inorganic phosphorus, G1, n=162 | 0 |
| Inorganic phosphorus, G2, n=162 | 52 |
| Inorganic phosphorus, G3, n=162 | 10 |
| Inorganic phosphorus, G4, n=162 | 0 |
| Creatinine, G0, n=162 | 149 |
| Creatinine, G1, n=162 | 8 |
| Creatinine, G2, n=162 | 3 |
| Creatinine, G3, n=162 | 0 |
| Creatinine, G4, n=162 | 2 |
Hematology parameters were summarized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0: G0, none; G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Hematology parameters included: hemoglobin (increased), hemoglobin (anemia), lymphocyte count (increased), lymphocyte count (decreased), total absolute neutrophil count (ANC), platelet count and white blood cell (WBC) count. Baseline values were obtained at Day 1. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). The maximum post-Baseline toxicity grade includes any scheduled or unscheduled post-Baseline assessment during.
| Participants | Eltrombopag |
|---|---|
| Hemoglobin (increased), G0, n=162 | 143 |
| Hemoglobin (increased), G1, n=162 | 17 |
| Hemoglobin (increased), G2, n=162 | 1 |
| Hemoglobin (increased), G3, n=162 | 1 |
| Hemoglobin (increased), G4, n=162 | 0 |
| Hemoglobin (anemia), G0, n=162 | 55 |
| Hemoglobin (anemia), G1, n=162 | 63 |
| Hemoglobin (anemia), G2, n=162 | 31 |
| Hemoglobin (anemia), G3, n=162 | 13 |
| Hemoglobin (anemia), G4, n=162 | 0 |
| Lymphocyte count (increased), G0, n=161 | 122 |
| Lymphocyte count (increased), G1, n=161 | 0 |
| Lymphocyte count (increased), G2, n=161 | 39 |
| Lymphocyte count (increased), G3, n=161 | 0 |
| Lymphocyte count (increased), G4, n=161 | 0 |
| Lymphocyte count (decreased), G0, n=161 | 86 |
| Lymphocyte count (decreased), G1, n=161 | 36 |
| Lymphocyte count (decreased), G2, n=161 | 26 |
| Lymphocyte count (decreased), G3, n=161 | 13 |
| Lymphocyte count (decreased), G4, n=161 | 0 |
| Total ANC, G0, n=161 | 140 |
| Total ANC, G1, n=161 | 12 |
| Total ANC, G2, n=161 | 3 |
| Total ANC, G3, n=161 | 3 |
| Total ANC, G4, n=161 | 3 |
| Platelet count, G0, n=162 | 2 |
| Platelet count, G1, n=162 | 8 |
| Platelet count, G2, n=162 | 3 |
| Platelet count, G3, n=162 | 26 |
| Platelet count, G4, n=162 | 123 |
| WBC, G0, n=162 | 135 |
| WBC, G1, n=162 | 21 |
| WBC, G2, n=162 | 3 |
| WBC, G3, n=162 | 3 |
| WBC, G4, n=162 | 0 |
On-therapy + 1 day is defined as AEs started between the first dose of eltrombopag and up to the day after the last dose of eltrombopag; \>1 to 30 days post therapy is defined as AEs that started more than 1 day and up to 30 days after the last dose of eltrombopag; \>30 days post therapy is defined as AEs started that started more than 30 days after the last dose of eltrombopag. An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.
| Participants | Eltrombopag |
|---|---|
| Any AE, on-therapy + 1 day | 141 |
| Any SAE, on-therapy + 1 day | 41 |
| Any AE, >1 to 30 days post therapy | 12 |
| Any SAE, >1 to 30 days post therapy | 5 |
| Any AE, >30 days post therapy | 9 |
| Any SAE, >30 days post therapy | 1 |
Collected over On-treatment SAEs and non-serious AEs are defined as events occuring from the start of the treatment (Day 1) up to Week 104 and including the follow-up period of up to 6 months (only 4 weeks for most participants) (up to approximately 2.5 years).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eltrombopag | — | 42/162 (25.9%) | 114/162 (70.4%) |
| Event | Eltrombopag |
|---|---|
| Gastrointestinal haemorrhageGastrointestinal disorders | 3/162 |
| MenorrhagiaReproductive system and breast disorders | 3/162 |
| AnaemiaBlood and lymphatic system disorders | 2/162 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/162 |
| VertigoEar and labyrinth disorders | 2/162 |
| Gingival bleedingGastrointestinal disorders | 2/162 |
| NauseaGastrointestinal disorders | 2/162 |
| VomitingGastrointestinal disorders | 2/162 |
| FatigueGeneral disorders | 2/162 |
| Tooth abscessInfections and infestations | 2/162 |
| Event | Eltrombopag |
|---|---|
| HeadacheNervous system disorders | 30/162 |
| CoughRespiratory, thoracic and mediastinal disorders | 24/162 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 22/162 |
| DiarrhoeaGastrointestinal disorders | 21/162 |
| NauseaGastrointestinal disorders | 21/162 |
| Upper respiratory tract infectionInfections and infestations | 20/162 |
| PyrexiaGeneral disorders | 18/162 |
| NasopharyngitisInfections and infestations | 17/162 |
| Back painMusculoskeletal and connective tissue disorders | 17/162 |
| PetechiaeSkin and subcutaneous tissue disorders | 17/162 |
All Treated Subjects (ATS) Population: all participants who received at least one dose of study medication excluding the 5 participants from Center 082877.
| Age, Continuous(Years) | Eltrombopag |
|---|---|
| Mean | 43.1 ± 16.31 |
| Sex: Female, Male(Participants) | Eltrombopag |
|---|---|
| Female | 104 |
| Male | 58 |
| Race/Ethnicity, Customized(Participants) | Eltrombopag |
|---|---|
| Asian - Central/South Asian Heritage | 47 |
| Asian - East Asian Heritage | 32 |
| Asian - South East Asian Heritage | 1 |
| White - White/Caucasian/European Heritage | 81 |
| Missing | 1 |
The record gives a start of May 2010, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag